EVOLUS INC (EOLS) Stock Price, Quote, News and Overview
NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock - Currency: USD
EOLS Quote, Performance and Key Statistics
13.99
-0.63 (-4.31%)
The current stock price of EOLS is 13.99 USD. In the past month the price decreased by -0.21%. In the past year, price increased by 1.97%.
EOLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About EOLS
Company Profile
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 322 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Company Info
EVOLUS INC
520 Newport Center Dr Ste 1200
Newport Beach CALIFORNIA 92660 US
CEO: David Moatazedi
Employees: 304
Company Website: https://www.evolus.com
Investor Relations: http://investors.evolus.com
Phone: 19492844555
EVOLUS INC / EOLS FAQ
What is the stock price of EVOLUS INC today?
The current stock price of EOLS is 13.99 USD. The price decreased by -4.31% in the last trading session.
What is the ticker symbol for EVOLUS INC stock?
The exchange symbol of EVOLUS INC is EOLS and it is listed on the Nasdaq exchange.
On which exchange is EOLS stock listed?
EOLS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EVOLUS INC stock?
13 analysts have analysed EOLS and the average price target is 24.19 USD. This implies a price increase of 72.9% is expected in the next year compared to the current price of 13.99. Check the EVOLUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EVOLUS INC worth?
EVOLUS INC (EOLS) has a market capitalization of 885.85M USD. This makes EOLS a Small Cap stock.
How many employees does EVOLUS INC have?
EVOLUS INC (EOLS) currently has 304 employees.
What are the support and resistance levels for EVOLUS INC (EOLS) stock?
EVOLUS INC (EOLS) has a support level at 13.17 and a resistance level at 14.75. Check the full technical report for a detailed analysis of EOLS support and resistance levels.
Is EVOLUS INC (EOLS) expected to grow?
The Revenue of EVOLUS INC (EOLS) is expected to grow by 32.14% in the next year. Check the estimates tab for more information on the EOLS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EVOLUS INC (EOLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EOLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EOLS, evaluating the profitability, health, valuation and growth aspects
- EVOLUS INC (EOLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EVOLUS INC (EOLS) Sales and EPS estimates to see what analysts future expectations are.
- EVOLUS INC (EOLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EVOLUS INC (EOLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- EVOLUS INC (EOLS) Stock Chart to make your own analysis
- EVOLUS INC (EOLS) Latest news and press-releases to stay up to date.
Does EVOLUS INC (EOLS) stock pay dividends?
EOLS does not pay a dividend.
When does EVOLUS INC (EOLS) report earnings?
EVOLUS INC (EOLS) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of EVOLUS INC (EOLS)?
EVOLUS INC (EOLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the Short Interest ratio of EVOLUS INC (EOLS) stock?
The outstanding short interest for EVOLUS INC (EOLS) is 11.65% of its float. Check the ownership tab for more information on the EOLS short interest.
EOLS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to EOLS. When comparing the yearly performance of all stocks, EOLS turns out to be only a medium performer in the overall market: it outperformed 67.86% of all stocks.
EOLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EOLS. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative.
EOLS Financial Highlights
Over the last trailing twelve months EOLS reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 35.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.15% | ||
| ROE | -941.6% | ||
| Debt/Equity | 20.58 |
EOLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to EOLS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 55.54% and a revenue growth 32.14% for EOLS